Ironwood Pharmaceuticals, Inc. (IRWD) Stock Analysis & Investment Frameworks
Ironwood Pharmaceuticals, Inc. (IRWD) stock analysis on Invetso. Review Ironwood Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Ironwood Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
Ironwood Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $586.60M
- Revenue: $296.15M
- P/E Ratio: 23.67
- ROE: -57.40%
- ROIC: 57.85%
- Dividend Yield: N/A
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
Ironwood Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes Ironwood Pharmaceuticals, Inc. (IRWD) across the following frameworks:
- Ironwood Pharmaceuticals, Inc. 10Y Growth Potential
- Ironwood Pharmaceuticals, Inc. Scenario Analysis
- Ironwood Pharmaceuticals, Inc. Risks & Opportunities
- Ironwood Pharmaceuticals, Inc. Economic Moat
- Ironwood Pharmaceuticals, Inc. Business Model
- Ironwood Pharmaceuticals, Inc. Management
- Ironwood Pharmaceuticals, Inc. SWOT Analysis
- Ironwood Pharmaceuticals, Inc. Porter's 5 Forces
- Ironwood Pharmaceuticals, Inc. PESTLE Analysis
- Ironwood Pharmaceuticals, Inc. ESG Analysis